Preclinical efficacy and safety of a novel lentiviral vector for ex vivo gene therapy of p47phox-deficient chronic granulomatous disease.
Chronic granulomatous disease is a primary immunodeficiency caused by mutations in the genes encoding subunits of the nicotinamide adenine dinucleotide phosphate oxidase complex, resulting in impaired antimicrobial activity of phagocytes. Patients suffer from recurrent infections and inflammation with life-threatening long-term complications. We developed a self-inactivating lentiviral vector for ex vivo gene therapy of p47phox-deficient chronic granulomatous disease…